AIM ImmunoTech CEO letter outlines Ampligen role after daraxonrasib approval
AIM ImmunoTech said Ampligen’s differentiated mechanism may support a pancreatic-cancer role following FDA approval of daraxonrasib, citing retrospective survival data and targeting DURIPANC Phase 2 readouts in 2027.
Story updates
01:01:59 PM UTC
SquawkNews
AIM ImmunoTech issued a CEO letter positioning Ampligen’s differentiated mechanism and potential role in pancreatic cancer following FDA approval of daraxonrasib, citing retrospective survival data and timelines for its DURIPANC Phase 2 readouts in 2027.Material DetailsContext by AI AnalystThis is…